Amylin Pharmaceuticals (AMLN) is Undervalued

---

var addthis_product = ‘wpp-252′;
var addthis_config = {“data_track_clickback”:true};var addthis_options = “facebook,twitter,linkedin,email”Shares of Amylin Pharmaceuticals (AMLN) plummeted 25% today on news its promising diabetes drug Bydureon came up short in a head-to-head comparison with Novo Nordisk’s Victoza. While the results were certainly bad good news for Amylin, today’s market reaction was too severe for the following reasons: • Bydureon is still an effective treatment option for [...]

Visit HedgeFundLIVE.com.